Oncternal Therapeutics, Inc.
ONCT
|
$8.97
4.3%
4.12%
4.5K
|
Health Technology
(0.0% 1d) (11.3% 1m) (2601.2% 1y) (0.0% 2d) (-1.0% 3d) (0.7% 7d) (13.42% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 24,122,420
http://www.oncternal.com
Sec Filling | Patents | 14 employees
(US) Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. It focuses on drug development of untapped biological pathways implicated in cancer progression. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.
cancer treatment
add to watch list Paper trade email alert is off
Press-releases
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
| Email alert
Add to watchlist
onct-534 first cancer treatment for study
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
Published: 2024-03-15 (Crawled : 13:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -4.32%
H: 8.26%
C: 7.19%
cancer treatment key
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -0.22%
H: 3.9%
C: 3.9%
business year update therapeutics financial results
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-06 (Crawled : 22:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -3.64%
H: 1.02%
C: 1.02%
conference life sciences therapeutics
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-01 (Crawled : 14:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -2.66%
H: 6.01%
C: -0.53%
award nasdaq therapeutics
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - February 1, 2024
Published: 2024-02-01 (Crawled : 22:00) - biospace.com/
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -2.66%
H: 6.01%
C: -0.53%
award nasdaq therapeutics
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: 4.93%
H: 3.89%
C: 0.14%
onct-534 cancer treatment therapeutics study
Oncternal Therapeutics Announces Reverse Stock Split
Published: 2024-01-04 (Crawled : 14:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -3.25%
H: 8.33%
C: -21.96%
therapeutics
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-02 (Crawled : 14:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: 0.43%
H: 6.28%
C: 2.88%
award nasdaq therapeutics
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
Published: 2023-12-26 (Crawled : 14:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -16.39%
H: 19.98%
C: 18.2%
onct-808 therapeutics study
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10